Is the antiviral activity of zinc ions maintained across physiologically relevant temperatures?

Label:chem

Topic
Personal protective equipment (PPE) experiences temperatures ranging from room temperature to body temperature (≈37 °C).
Answer
es. Hemagglutination assays performed after 1 h of zinc treatment at 4 °C, 26 °C, and 37 °C revealed comparable, significant inhibition at 26 °C and 37 °C, with slightly more variable but still measurable inhibition at 4 °C. Thus, zinc-embedded PPE remains effective under typical environmental and body temperatures.
Return to Home Chemical List
Knowledge you may be interested in
Does zinc-mediated inactivation compromise the structural integrity of the IAV particle? How do zinc ions affect influenza A virus (IAV) hemagglutinin function and virus infectivity? What role does desloratadine or levocetirizine play when added to oral isotretinoin in the treatment of acne vulgaris? What evidence supports the efficacy of relugolix combination therapy in endometriosis? How do clinical outcomes compare between relugolix monotherapy and combination therapy? Does relugolix combination therapy preserve BMD over extended treatment periods? What strategy has been developed to mitigate relugolix-induced BMD loss? How does relugolix monotherapy affect bone mineral density (BMD)? What is relugolix, and how does it function as a therapeutic agent in uterine diseases? Does combining diazepam with low-frequency rTMS produce additive or synergistic suppression of Ca²⁺ elevation? What is Cucurbitacin E (CuE) and where is it derived from? Does Cucurbitacin E (CuE) exhibit cytotoxicity toward 3T3-L1 adipocytes during adipogenesis? How does CuE influence lipid accumulation in differentiating 3T3-L1 adipocytes? Which key adipogenic transcription factors are down-regulated by Cucurbitacin E (CuE)? What molecular pathways are implicated in CuE-mediated inhibition of adipogenesis and lipogenesis? What is the overall conclusion regarding CuE’s potential as an anti-obesity agent? What is the role of synthetic angiotensin II (Giapreza®/AT2S) in the peri-operative management of kidney transplantation? Were there any safety concerns specific to angiotensin II (Giapreza®/AT2S) use? What is nicotine's proposed mechanism of neuroprotection in Parkinson’s disease (PD)? What were the findings of the meta-analysis regarding nicotine's effect on motor symptoms in PD patients?